Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS IG anti-kickback advisory opinions will be produced for a fee under interim final rule.

Executive Summary

HHS IG TO CHARGE FOR ANTI-KICKBACK ADVISORY OPINIONS under an interim final rule published in the Federal Register Feb. 18. The rule implements a requirement of the 1996 Kennedy/Kassebaum health insurance reform bill that the HHS Inspector General and the Department of Justice provide guidance upon request as to whether a particular arrangement violates federal anti-kickback laws under Medicare and Medicaid. Justice and the IG are proposing to bill for "actual costs incurred" in processing advisory opinion requests. The HHS Office of the Inspector General began accepting requests for legally binding advisory opinions Feb. 21.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel